TheraCryf Advances Addiction Treatment Program with Strategic Developments

The latest update is out from Evgen Pharma ( (GB:TCF) ).

TheraCryf plc has announced significant progress in its addiction-treatment program, Ox-1, which is on track for regulatory submission by the end of 2026. The company has appointed Pharmaron as its development partner and is scaling up manufacturing to meet regulatory requirements. Financially, TheraCryf reported a post-tax loss of £1.3m, with a cash runway extending to the end of 2026. The addiction market, valued at over $40bn, presents a substantial opportunity for TheraCryf, as the company aims to address the human and economic costs of addiction with its promising treatment.

Spark’s Take on GB:TCF Stock

According to Spark, TipRanks’ AI Analyst, GB:TCF is a Neutral.

Evgen Pharma’s overall stock score of 49 reflects ongoing financial and operational challenges, including declining revenues and losses. While the technical analysis shows mixed momentum, recent corporate events provide a positive outlook with strategic initiatives aimed at improving financial stability and advancing key drug development programs.

To see Spark’s full report on GB:TCF stock, click here.

More about Evgen Pharma

TheraCryf plc is a clinical stage drug development company that focuses on brain disorders, including addiction, anxiety, fatigue, narcolepsy, glioblastoma, and neurodevelopmental disorders. The company aims to generate compelling data sets for preclinical and clinical proof of concept and partners its clinical programs with mid-size to large pharmaceutical companies for larger trials and commercialization. TheraCryf collaborates with major universities and hospitals and is headquartered in Alderley Park, Cheshire.

Average Trading Volume: 3,820,006

Technical Sentiment Signal: Sell

Current Market Cap: £4.08M

Learn more about TCF stock on TipRanks’ Stock Analysis page.